Therapeutic | Sonelokimab2 |
Target | IL17F |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGRTYDAMGWLRQAPGKEREFVAAISGSGDDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCATRRGLYYVWDANDYENWGQGTLVTVSS |
Light Chain | na |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Trispecific Single Domains (VH-VH'-VH''); Entry 2 |
Isotype | na |
Highest Clinical Trial (August '23) | Phase-II |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | |
INN Year Proposed | 2019 |
INN Year Recommended | 2020 |
Companies Involved | Ablynx, Avillion, MoonLake Immunotherapeutics, Merck Serono |
Conditions Approved | na |
Conditions Active | Hidradenitis suppurativa, Psoriasis, Psoriatic arthritis, Ankylosing spondylitis |
Conditions Discontinued | na |
Notes | VH'' portion. Joint entry with Sonelokimab1 (trispecific). Humanised: Llama/Human |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]